Skip to main content

Advertisement

SpringerLink
Log in

Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18FDG 18F-FDG PET-CT) are standard procedures for staging multiple myeloma (MM). Diffusion-weighted sequences applied to whole-body MRI (WB-DWI) improve its sensitivity. We compared the number of MM bone focal lesions (FLs) detected by 18F-FDG PET-CT and WB-DWI and evaluated the diagnostic performance of 18F-FDG PET-CT for diffuse infiltration. Thirty newly diagnosed MM patients prospectively underwent 18F-FDG PET-CT and WB-DWI. The criteria for skeletal region positivity were ≥ 1 focal bone lesions (FLs) and/or diffuse disease. MRI with the MY-RADS criteria was used as a reference standard for the diagnosis of diffuse infiltration. 18F-FDG PET-CT and WB-DWI were both interpreted as positive in 28/30 patients with an agreement of 1.00 (95% CI 0.77–1.00) between the two methods. The mean numbers of FLs were 16.7 detected by 18F-FDG PET-CT and 23.9 detected by WB-DWI (P = 0.028). WB-DWI detected more FLs in the skull (P = 0.001) and spine (P = 0.006). Agreement assessed using the prevalence and bias-corrected kappa index was moderate (0.40–0.60) for the spine, sternum–ribs and upper limbs and substantial (0.60–0.80) for the pelvis and lower limbs. As regards the diagnosis of diffuse bone marrow infiltration, the sensitivity, specificity and accuracy of 18F-FDG PET-CT were 0.75, 0.79 and 0.77, respectively. Although WB-DWI detected more FLs than did 18F-FDG PET-CT, there was no difference in the detection of bone disease on a per-patient basis. 18F-FDG PET-CT showed high performance, including for evaluation of diffuse infiltration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2.
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 31(9):1915–1921. https://doi.org/10.1038/leu.2016.380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet 385(9983):2197–2208. https://doi.org/10.1016/S0140-6736(14)60493-1

    Article  CAS  PubMed  Google Scholar 

  3. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068–2076. https://doi.org/10.1182/blood-2009-03-213280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989–5995. https://doi.org/10.1182/blood-2011-06-361386

    Article  CAS  PubMed  Google Scholar 

  5. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S (2013) Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 162(1):50–61. https://doi.org/10.1111/bjh.12346

    Article  CAS  PubMed  Google Scholar 

  6. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garcia-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The lancet oncology 20(6):e302–e312. https://doi.org/10.1016/S1470-2045(19)30309-2

    Article  PubMed  Google Scholar 

  7. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B (2013) Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood 121(10):1819–1823. https://doi.org/10.1182/blood-2012-08-451690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F (2017) Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(25):2911–2918. https://doi.org/10.1200/JCO.2017.72.2975

    Article  CAS  Google Scholar 

  9. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E (2017) Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The lancet oncology 18(4):e206–e217. https://doi.org/10.1016/S1470-2045(17)30189-4

    Article  PubMed  Google Scholar 

  10. Hillengass J, Bauerle T, Bartl R, Andrulis M, McClanahan F, Laun FB, Zechmann CM, Shah R, Wagner-Gund B, Simon D, Heiss C, Neben K, Ho AD, Schlemmer HP, Goldschmidt H, Delorme S, Stieltjes B (2011) Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 153(6):721–728. https://doi.org/10.1111/j.1365-2141.2011.08658.x

    Article  PubMed  Google Scholar 

  11. Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, Davies FE, Morgan GJ, deSouza NM (2014) Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 271(3):785–794. https://doi.org/10.1148/radiol.13131529

    Article  PubMed  Google Scholar 

  12. Moulopoulos LA, Dimopoulos MA, Christoulas D, Kastritis E, Anagnostou D, Koureas A, Roussou M, Gavriatopoulou M, Migkou M, Iakovaki M, Gkotzamanidou M, Tasidou A, Terpos E (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 24(6):1206–1212. https://doi.org/10.1038/leu.2010.70

    Article  CAS  PubMed  Google Scholar 

  13. Hillengass J, Fechtner K, Weber MA, Bauerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(9):1606–1610. https://doi.org/10.1200/JCO.2009.25.5356

    Article  Google Scholar 

  14. Spinnato P, Bazzocchi A, Brioli A, Nanni C, Zamagni E, Albisinni U, Cavo M, Fanti S, Battista G, Salizzoni E (2012) Contrast enhanced MRI and (1)(8)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol 81(12):4013–4018. https://doi.org/10.1016/j.ejrad.2012.06.028

    Article  CAS  PubMed  Google Scholar 

  15. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The lancet oncology 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5

    Article  PubMed  Google Scholar 

  16. Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF (2008) Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 190(4):1097–1104. https://doi.org/10.2214/AJR.07.2635

    Article  PubMed  Google Scholar 

  17. Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bello M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauvie S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M (2016) 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30(2):417–422. https://doi.org/10.1038/leu.2015.291

    Article  CAS  PubMed  Google Scholar 

  18. Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L (2014) State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol 83(12):2203–2223. https://doi.org/10.1016/j.ejrad.2014.09.012

    Article  PubMed  Google Scholar 

  19. Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, Blackledge MD, Abildgaard N, Ostergaard B, Schlemmer HP, Landgren O, Asmussen JT, Kaiser MF, Padhani A (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 291(1):5–13. https://doi.org/10.1148/radiol.2019181949

    Article  PubMed  Google Scholar 

  20. Duvauferrier R, Valence M, Patrat-Delon S, Brillet E, Niederberger E, Marchand A, Rescan M, Guillin R, Decaux O (2013) Current role of CT and whole body MRI in multiple myeloma. Diagn Interv Imaging 94(2):169–183. https://doi.org/10.1016/j.diii.2012.12.001

    Article  CAS  PubMed  Google Scholar 

  21. Byrt T, Bishop J, Carlin JB (1993) Bias, prevalence and kappa. J Clin Epidemiol 46(5):423–429

    Article  CAS  Google Scholar 

  22. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33(26):2863–2869. https://doi.org/10.1200/JCO.2015.61.2267

    Article  CAS  Google Scholar 

  23. Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, Haberkorn U, Schlemmer HP, Delorme S, Dimitrakopoulou-Strauss A (2015) Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging 5(5):479–492

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, Wen B, He Y (2019) Comparison of whole-body DWI and (18)F-FDG PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma. AJR Am J Roentgenol 213(3):514–523. https://doi.org/10.2214/AJR.18.20989

    Article  PubMed  Google Scholar 

  25. Pawlyn C, Fowkes L, Otero S, Jones JR, Boyd KD, Davies FE, Morgan GJ, Collins DJ, Sharma B, Riddell A, Kaiser MF, Messiou C (2016) Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? Leukemia 30(6):1446–1448. https://doi.org/10.1038/leu.2015.338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97(11):1761–1767. https://doi.org/10.3324/haematol.2012.065698

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130(1):30–34. https://doi.org/10.1182/blood-2017-03-774422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A, Zerbib P, Pigneur F, Cuenod CA, Bessalem H, Cavet M, Boutekadjirt A, Haioun C, Luciani A (2015) Intravoxel incoherent motion diffusion-weighted imaging of multiple myeloma lesions: correlation with whole-body dynamic contrast agent-enhanced MR imaging. Radiology 277(3):773–783. https://doi.org/10.1148/radiol.2015141728

    Article  PubMed  Google Scholar 

  29. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B (2013) Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 98(1):71–78. https://doi.org/10.3324/haematol.2012.066555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lecouvet FE, Vande Berg BC, Michaux L, Malghem J, Maldague BE, Jamart J, Ferrant A, Michaux JL (1998) Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 209(3):653–660. https://doi.org/10.1148/radiology.209.3.9844655

    Article  CAS  PubMed  Google Scholar 

  31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92(1):50–55

    Article  Google Scholar 

  32. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A (2012) Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 53(10):1876–1881. https://doi.org/10.3109/10428194.2012.677535

    Article  PubMed  Google Scholar 

  33. Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bello M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E (2018) Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45(5):712–719. https://doi.org/10.1007/s00259-017-3909-8

    Article  PubMed  Google Scholar 

  34. Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jorg G, Samnick S, Herrmann K, Buck AK, Einsele H, Luckerath K (2016) 11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics 6(2):254–261. https://doi.org/10.7150/thno.13921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL (2014) The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma. Eur Radiol 24(11):2754–2765. https://doi.org/10.1007/s00330-014-3324-5

    Article  PubMed  Google Scholar 

  36. Rasche L, Kortum KM, Raab MS, Weinhold N (2019) The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int J Mol Sci 20(5). https://doi.org/10.3390/ijms20051248

Download references

Acknowledgement

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/w8vkZn

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, CHU Bordeaux, 33000, Bordeaux, France

    Charles Mesguich, Laurence Bordenave & Elif Hindié

  2. INSERM U1035, University of Bordeaux, Bordeaux, France

    Charles Mesguich & Gerald Marit

  3. Haematology Department, CHU Bordeaux, 33000, Bordeaux, France

    Cyrille Hulin & Axelle Lascaux

  4. Radiology Department, CHU Bordeaux, 33000, Bordeaux, France

    Valerie Latrabe

Authors
  1. Charles Mesguich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyrille Hulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valerie Latrabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axelle Lascaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurence Bordenave
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elif Hindié
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerald Marit
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CM, GM and EH designed the study. CM, CH, VL and AL collected the data. CM, EH and GM analysed the data. CM, EH, GM and LB wrote the manuscript. All authors approved the submitted version of the manuscript.

Corresponding author

Correspondence to Charles Mesguich.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Institutional Ethics Committee protocol no. 352/18) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mesguich, C., Hulin, C., Latrabe, V. et al. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Ann Hematol 99, 2869–2880 (2020). https://doi.org/10.1007/s00277-020-04265-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04265-2

Keywords

Search

Navigation